Robo Medical Secures Tens of Millions in Funding for EndoFaster and EndoDreams Development
China-based Robo Medical Technology Co. has closed a strategic funding round amounting to “tens of...
CanSino Bio Receives NMPA Approval for Phase I/II Trial of Recombinant Polio Vaccine
China-based CanSino Biologics Inc., (HKG: 6185) announced that it and its subsidiary CanSino (Shanghai) Biotechnology...
Yifan Pharma’s Generic Glycerol Phenylbutyrate Accepted for NMPA Review
China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced that the National Medical Products Administration (NMPA)...
Hengrui Pharmaceuticals’ SHR-8068 Gains NMPA Approval for NSCLC and Colorectal Cancer Trials
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical...
Fosun Pharma’s Zhejiang Xinghao Unit Initiates Phase Ib Study for COPD DPP-1 Inhibitor XH-S004
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its Zhejiang Xinghao...
Legend Biotech’s Carvykti Achieves USD 439 Million in Q2 2025 Sales
China-based Legend Biotech Corporation (NASDAQ: LEGN) reported that sales of Carvykti reached USD 439 million...
Buchang Pharma Subsidiary Establishes Shaanxi Buchang MedData with Lingyishushu
Shandong Buchang Chuanfang, a subsidiary of China-based Buchang Pharma (SHA: 603858), announced the establishment of...
Novartis Reports Double-Digit Growth in Q2 and 1H25, Driven by Key Brands
Swiss pharmaceutical giant Novartis (NYSE: NVS) reported double-digit growth in both revenue and net income...
Takeda’s Oveporexton Meets All Endpoints in Phase 3 Narcolepsy Type 1 Trials
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) announced that both Phase 3 randomized, double-blind, placebo-controlled...
PHASE Scientific Partners with Lumos Diagnostics to Launch FebriDx in US Respiratory Market
China-based PHASE Scientific has entered into an exclusive distribution agreement with Lumos Diagnostics to introduce...
Daiichi Sankyo and AstraZeneca Submit Enhertu Application for HER2-Positive Gastric Cancer in China
Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have submitted a supplemental new-drug application...
Johnson & Johnson Reports 5.8% Sales Growth in 2025Q2, Increases Full-Year Guidance
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced its second-quarter 2025 (2025Q2) results, reporting...
Konruns’ KC1036 Proposed for CDE’s SPARK Program to Accelerate Pediatric Ewing’s Sarcoma Treatment Development
Beijing-based Konruns Pharmaceutical Co., Ltd. (SHA: 603590) announced on Wednesday that China’s Center for Drug...
Hainan Boao Research Hospital Secures Approval for China’s First Medical-Food Import for Rare Metabolic Disorders
Hainan Boao Research Hospital, operated by Shanghai’s Ruijin Hospital, has obtained provincial approval to import...
Sanofi’s Gene Therapy SAR446597 Secures FDA Fast Track for Geographic Atrophy
France-based Sanofi (NASDAQ: SNY) announced that its one-time intravitreal gene therapy SAR446597 has received FDA...
Tcelltech Secures USD 40 Million Series B Funding for TX-103 CAR-T Therapy Development
China-based Tcelltech Ltd., a developer of T-cell immunotherapies, has reportedly secured close to USD 40...
Hengrui Pharma and Kailera Announce Positive Phase III Results for HRS9531 in Obesity Treatment
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) and its US partner Kailera Therapeutics, Inc....
Haisco Pharma Receives FDA Approval for Clinical Trials of Autoimmune Drug HSK47388
China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) announced that it has received clinical trial...
Danaher’s Cytiva Collaborates with CorrectSequence on Gene Therapy LNP Delivery System
US-based science and tech services giant Danaher Corporation (NYSE: DHR) announced an ongoing collaboration between...
AstraZeneca’s Baxdrostat Meets Primary and Secondary Endpoints in Phase III BaxHTN Trial
UK-based AstraZeneca (AZ, NASDAQ: AZN) announced that baxdrostat has achieved both primary and secondary endpoints in the...